Amphastar Pharmaceuticals (AMPH) to Release Quarterly Earnings on Thursday

Amphastar Pharmaceuticals (NASDAQ:AMPH) is anticipated to issue its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect the company to announce earnings of $0.97 per share and revenue of $190.48 million for the quarter. Interested persons can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Friday, February 27, 2026 at 4:00 PM ET.

Amphastar Pharmaceuticals Trading Up 0.7%

Shares of NASDAQ AMPH opened at $28.66 on Thursday. Amphastar Pharmaceuticals has a twelve month low of $20.39 and a twelve month high of $32.69. The firm has a market cap of $1.32 billion, a PE ratio of 12.68, a price-to-earnings-growth ratio of 5.19 and a beta of 0.88. The business has a fifty day simple moving average of $27.14 and a two-hundred day simple moving average of $26.85. The company has a quick ratio of 2.21, a current ratio of 3.12 and a debt-to-equity ratio of 0.78.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on AMPH. Zacks Research downgraded Amphastar Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Friday, November 14th. Needham & Company LLC cut their target price on shares of Amphastar Pharmaceuticals from $36.00 to $34.00 and set a “buy” rating on the stock in a research report on Friday, November 7th. Barclays began coverage on shares of Amphastar Pharmaceuticals in a research report on Tuesday, December 9th. They issued an “equal weight” rating and a $30.00 price target for the company. Finally, Weiss Ratings reissued a “hold (c-)” rating on shares of Amphastar Pharmaceuticals in a report on Monday, December 29th. Two analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $31.00.

Insider Buying and Selling

In related news, Director Richard K. Prins sold 4,179 shares of the stock in a transaction that occurred on Tuesday, November 25th. The shares were sold at an average price of $27.10, for a total transaction of $113,250.90. Following the completion of the sale, the director owned 35,183 shares of the company’s stock, valued at $953,459.30. This represents a 10.62% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Floyd F. Petersen sold 2,426 shares of Amphastar Pharmaceuticals stock in a transaction on Friday, December 12th. The stock was sold at an average price of $25.92, for a total transaction of $62,881.92. Following the completion of the transaction, the director directly owned 71,368 shares in the company, valued at $1,849,858.56. This represents a 3.29% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 18,129 shares of company stock worth $477,176 in the last 90 days. 27.50% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Amphastar Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in AMPH. Rafferty Asset Management LLC purchased a new stake in shares of Amphastar Pharmaceuticals during the fourth quarter valued at $206,000. Commonwealth Equity Services LLC lifted its position in Amphastar Pharmaceuticals by 11.2% during the 4th quarter. Commonwealth Equity Services LLC now owns 8,742 shares of the company’s stock worth $234,000 after acquiring an additional 882 shares during the period. Janney Montgomery Scott LLC grew its stake in Amphastar Pharmaceuticals by 6.2% during the 4th quarter. Janney Montgomery Scott LLC now owns 14,230 shares of the company’s stock valued at $381,000 after purchasing an additional 825 shares during the last quarter. Franklin Resources Inc. acquired a new position in shares of Amphastar Pharmaceuticals in the third quarter valued at about $254,000. Finally, PDT Partners LLC purchased a new position in shares of Amphastar Pharmaceuticals in the second quarter worth about $336,000. 65.09% of the stock is currently owned by hedge funds and other institutional investors.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company headquartered in Rancho Cucamonga, California. Founded in 2004, Amphastar focuses on the development, manufacturing and commercialization of injectable and inhalation products. The company’s manufacturing facilities in California produce both generic and proprietary formulations designed to address urgent and chronic medical conditions.

Amphastar’s portfolio includes a range of injectable generics such as epinephrine, naloxone and lidocaine, serving hospital, emergency medical and retail pharmacy channels.